The Life Sciences team advised Hansoh Pharmaceutical Group Co., Ltd., (“Hansoh Pharma”) on IP aspects associated with entering into an exclusive license agreement and strategic investment with Avere Therapeutics, Inc. (“Avere”), an investee company of Hansoh Pharma focused on advancing oral therapies for IL-23 driven inflammatory diseases. Pursuant to the license agreement, Hansoh Pharma has granted Avere the exclusive license to develop, manufacture, and commercialize HS-20118 (AVR-001), a cyclic peptide interleukin-23 receptor antagonist, globally (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan). Hansoh Pharma is eligible to receive upfront payments totaling $120 million and up to $2.18 billion in milestone payments associated with development and sales, as well as mid-single- to low-double-digit royalties on future sales.
Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with the mission of “Continuous innovation for better life.” The company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism, and immunology. Consistently ranked among the Top 100 Global Pharmaceutical Enterprises and the Top 3 China’s Best Industrial Enterprises in Pharmaceutical R&D Pipeline, Hansoh Pharma is recognized as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise.
The Goodwin team was led by Bill Christiansen, Daryl Wiesen, Linnea Cipriano, Xixi Sun, and Yingying Cai.
For more information on the deal, please read the press release.